← Eichor
Condition: Ii Iiib Stages Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Ii Iiib Stages

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Phase 1 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT04703101A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
Phase 2 · 1 location(s) · Oslo University Hospital · NCT06651151Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 · 345 location(s) · National Cancer Institute (NCI) · NCT03191149TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemo
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330037Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Guangzhou Medical Universit · NCT06383728Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagn
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT02918474Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Phase N/A · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT00899301Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
Phase 2 · 2 location(s) · Guangdong Association of Clinical Trials · NCT07120698Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Canc
Phase 1 · 4 location(s) · Emory University · NCT06324240A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Parti
Phase 3 · 267 location(s) · Merck Sharp & Dohme LLC · NCT06312137A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT07428044Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04789681Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly S
NA · 1 location(s) · Roswell Park Cancer Institute · NCT03880422D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage II
Phase 3 · 1 location(s) · Guangdong Provincial People's Hospital · NCT07016126A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
Phase 2 · 1 location(s) · Zhejiang University · NCT05837052Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06170177A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT05104788Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung
Phase 3 · 1151 location(s) · National Cancer Institute (NCI) · NCT04267848MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT05286957Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harbor
Phase 3 · 199 location(s) · Boehringer Ingelheim · NCT07195695Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT06734182Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patie
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04751409Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cann
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT04169763Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05295212Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lu
Phase 2 · 21 location(s) · Fundación GECP · NCT07153445SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Phase 3 · 1 location(s) · Nanjing Sanhome Pharmaceutical, Co., Ltd. · NCT06080776Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Phase 2 · 1 location(s) · University Hospital Heidelberg · NCT04865250Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Can
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05417308
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.